PureTech's Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial

PureTech Health (PRTC) announced positive Phase 2b trial results for deupirfenidone (LYT-100) in treating idiopathic pulmonary fibrosis (IPF), showing a statistically significant slowing of lung function decline compared to placebo and durability of this effect over 52 weeks. Specifically, the rate of FVC decline with deupirfenidone 825 mg TID was -21.5 mL at 26 weeks, similar to healthy older adults, and -32.8 mL over 52 weeks; the company plans to meet with the FDA before the end of Q3 2025 to discuss a Phase 3 trial, targeted for year-end.

Analysis

PureTech Health's deupirfenidone (LYT-100) has demonstrated compelling efficacy and durability in its Phase 2b ELEVATE IPF trial for idiopathic pulmonary fibrosis (IPF). The 825 mg TID dose achieved a statistically significant 80.9% reduction in lung function decline, as measured by Forced Vital Capacity (FVC), versus placebo at 26 weeks (-21.5 mL vs. -112.5 mL, p=0.02), an effect approximately 50% greater than that observed for pirfenidone 801 mg TID (54.1% reduction) in the same trial. Preliminary open-label extension data support this durability, with a -32.8 mL FVC decline over 52 weeks for the deupirfenidone 825 mg TID arm, a rate similar to the expected natural decline in healthy older adults. Furthermore, deupirfenidone demonstrated a statistically significant benefit in delaying time to IPF progression compared to placebo (hazard ratio = 0.439; p=0.0023). The drug exhibited a favorable tolerability profile, particularly when considering pharmacokinetic data showing approximately 50% increased drug exposure compared to pirfenidone 801 mg TID without a corresponding increase in tolerability issues, suggesting its deuterated structure may overcome dose-limiting adverse events associated with pirfenidone. PureTech plans to meet with the FDA by the end of Q3 2025, with the objective of initiating a Phase 3 trial by year-end 2025, positioning deupirfenidone as a potentially differentiated treatment option that could elevate the standard of care in a market with significant unmet need due to the progressive and fatal nature of IPF.

Key Decisions for Investors

• Investors should acknowledge the strong Phase 2b data for deupirfenidone, which indicates a potentially superior efficacy and tolerability profile compared to current IPF treatments, representing a significant clinical advancement.
• Monitor PureTech's upcoming regulatory interactions, specifically the planned FDA meeting by Q3 2025 and the subsequent initiation of a Phase 3 trial by year-end 2025, as these are critical de-risking milestones for the LYT-100 program.
• Consider the drug's potential to become a new standard of care in the IPF market if Phase 3 results replicate Phase 2b success, but remain cognizant of the inherent risks associated with clinical development in biotherapeutics.